The Effect of Zoledronic Acid Infusion in the Bone Loss Observed Following Denosumab Discontinuation in Postmenopausal Women With Low Bone Mass
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 07 Mar 2018
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- 09 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 11 Jul 2016 Planned End Date changed from 1 Jul 2018 to 1 Jul 2019.
- 11 Jul 2016 Planned primary completion date changed from 1 Jul 2018 to 1 Jul 2019.